Adeno-associated virus vector based gene therapy (VeonGen Therapeutics/Regeneron Pharmaceuticals)

N/A

Report date: 2025/06/18 10:44:00

Base Information

Drug NameAdeno-associated virus vector based gene therapy (VeonGen Therapeutics/Regeneron Pharmaceuticals)
Drug Alias NamevgAAV gene therapy
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRetinal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals IncVeonGen Therapeutics GmbH
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals IncVeonGen Therapeutics GmbH
Inactive CompaniesN/A
Active IndicationsRetinal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A